[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463441":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":49,"centralContacts":62,"locations":68,"responsibleParty":101,"collaborators":49,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":49,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":49,"studyType":116,"phases":117,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":71,"whyStopped":49,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,14,20,25,28,31,34,37],{"label":9,"type":10,"description":11,"interventionNames":12},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 \u002F Cohort 1","EXPERIMENTAL","Riboflavin Solution + Exposure to NXL system to achieve total energy level 3",[13],"Combination Product: NXL Energy 3",{"label":15,"type":16,"description":17,"interventionNames":18},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 \u002F Cohort 2A","ACTIVE_COMPARATOR","Riboflavin Solution + Exposure to NXL system to achieve total energy level 1",[19],"Combination Product: NXL Energy 1",{"label":21,"type":16,"description":22,"interventionNames":23},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 \u002F Cohort 2A","Riboflavin Solution + Exposure to NXL system to achieve total energy level 2",[24],"Combination Product: NXL Energy 2",{"label":26,"type":16,"description":11,"interventionNames":27},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 \u002F Cohort 2A",[13],{"label":29,"type":16,"description":17,"interventionNames":30},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 \u002F Cohort 2B",[19],{"label":32,"type":16,"description":22,"interventionNames":33},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 \u002F Cohort 2B",[24],{"label":35,"type":16,"description":11,"interventionNames":36},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 \u002F Cohort 2B",[13],{"label":38,"type":39,"description":40,"interventionNames":41},"Placebo Group 2 \u002F Cohort 2B","SHAM_COMPARATOR","Sham Solution with no exposure to NXL System",[42],"Combination Product: Sham Treatment",[44,50,54,58],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"COMBINATION_PRODUCT","NXL Energy 1","Riboflavin drops + NXL System to Total Energy Level 1",[15,29],null,{"type":45,"name":51,"description":52,"armGroupLabels":53,"otherNames":49},"NXL Energy 2","Riboflavin drops + NXL System to Total Energy Level 2",[21,32],{"type":45,"name":55,"description":56,"armGroupLabels":57,"otherNames":49},"NXL Energy 3","Riboflavin drops + NXL System to Total Energy Level 3",[9,26,35],{"type":45,"name":59,"description":60,"armGroupLabels":61,"otherNames":49},"Sham Treatment","Sham Drops and No exposure to NXL system",[38],[63],{"name":64,"role":65,"phone":66,"phoneExt":49,"email":67},"Marco Armijo","CONTACT","562-761-7965","marmijo@glaukos.com",[69,83,92],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":49},"Glaukos Investigative Site","RECRUITING","Dothan","Alabama","36301","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-85.39049,31.22323,{"lat":81,"lon":80},{"facility":70,"status":71,"city":84,"state":85,"zip":86,"country":75,"countryCode":76,"cosmosGeoPoint":87,"geoPoint":91,"contacts":49},"Teaneck","New Jersey","07666",{"type":78,"coordinates":88},[89,90],-74.01597,40.8976,{"lat":90,"lon":89},{"facility":70,"status":71,"city":93,"state":94,"zip":95,"country":75,"countryCode":76,"cosmosGeoPoint":96,"geoPoint":100,"contacts":49},"Westerville","Ohio","43082",{"type":78,"coordinates":97},[98,99],-82.92907,40.12617,{"lat":99,"lon":98},{"type":102,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100463441","phase-1-safety-and-efficacy-of-corneal-cross-linking-in-subjects-with-keratoconus-100463441",false,"NCT05314738","Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","Inclusion Criteria:\n\n* Provide written informed consent\n* Ability to hold gaze sufficiently stable for study testing\n* Willingness and ability to follow all instructions and comply with schedule for follow-up visits\n* Have a diagnosis of keratoconus\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to the test articles or components\n* Any disease causing abnormal topography other than keratoconus\n* Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications","ALL","18 Years","55 Years",{"count":114,"type":115},150,"ESTIMATED","INTERVENTIONAL",[118,119],"PHASE1","PHASE2","Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.",[122],"Progressive Keratoconus",[124,125,126,122],"Eye rubbing","Collagen cross-linking","Keratoconus","2024-07-04",{"date":129,"type":130},"2024-07-08","ACTUAL",{"date":132,"type":130},"2022-03-08",{"date":134,"type":115},"2026-02",{"name":5,"class":6},3]